Clinical Trial

Does Topical Ophthalmic Proparacaine 0.5% Prior to Probing and Irrigation Decrease Pain?

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated December 23, 2022 (before its estimated December 30, 2022 completion). Its status may not reflect the trial's current state.
Summary
Purpose: It is unknown whether instillation of a drop of anesthetic ophthalmic solution into the eye such as proparacaine hydrochloride 0.5% prior to probing and irrigation of the tear duct (lacrimal drainage) system improves participant comfort during the procedure. To date, there have been no formal studies evaluating the possible benefit of this pretreatment. Methods: Participants 18 years and older who present to the Louisiana State University or associated outpatient ophthalmology clinic(s) with a complaint of epiphora (excessive tearing) who necessitate bilateral lower lid probing and irrigation of the lacrimal drainage system will be enrolled in the study. One eye will be randomized to receive a drop of the anesthetic Proparacaine hydrochloride 0.5% and the other eye will receive a control drop of Balanced Salt Solution (BSS). Probing and irrigation will then be performed in the usual fashion. The participant will then be questioned via survey on a pain scale of 1-5 as to the amount of subjective pain experienced on each side during the procedure. Expected Results: Investigators expect participants will experience statistically significantly less pain in eyes that have received a drop of Proparacaine hydrochloride 0.5% prior to performance of probing and irrigation compared to the eyes which have received the control drop.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-12-15.
Status change: Recruiting → Completed 2025-08-12
Trial Details
NCT Number NCT05663684
Lead Sponsor Louisiana State University Health Sciences Center in New Orleans
Conditions Epiphora, Dacryostenosis, Dacryocystitis
Enrollment 145 participants
Start Date 2020-06-30
Primary Completion 2022-12-30 (estimated)
Study Completion 2023-01-31 (estimated)
Updated on ClinicalTrials.gov 2022-12-23